ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex Vivo Human Thrombosis Chamber Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00935506
Recruitment Status : Completed
First Posted : July 9, 2009
Last Update Posted : February 23, 2011
Sponsor:
Information provided by:
Bristol-Myers Squibb

Brief Summary:
Purpose of study is to evaluate a thrombosis chamber model

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Drug: Clopidogrel Drug: Aspirin Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Evaluation of an Experimental EX Vivo Thrombosis Chamber Model in Healthy Male Subjects
Study Start Date : July 2009
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Clopidogrel + Aspirin Drug: Clopidogrel
Tablets, Oral, 75 mg, Once daily, 8 days
Other Name: Plavix
Drug: Aspirin
Tablets, Oral, 325 mg, Once daily, 8 days



Primary Outcome Measures :
  1. Evaluate ex vivo thrombosis chamber model by assessing the effect of anti-platelet agents on thrombus formation [ Time Frame: Period 2, Day 8 ]

Secondary Outcome Measures :
  1. Assess variability of thrombosis chamber measurements [ Time Frame: Period 1 and Period 2 ]
  2. Assess relationship between platelet aggregation and thrombus formation [ Time Frame: Period 1 and Period 2 ]
  3. Safety and tolerability of multiple doses clopidogrel and aspirin [ Time Frame: From Day 1 through Study Discharge ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Subjects
  • BMI 18-30 kg/m²
  • Male ages 18-45

Exclusion Criteria:

  • Significant acute or chronic illness
  • History of abnormal bleeding or coagulation disorder, intracranial hemorrhage, or a family history of abnormal bleeding or coagulation disorder in a first degree relative under 50 years of age
  • Easy bruising
  • Smoking within 3 months prior to Day 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00935506


Locations
United States, New Jersey
Mds Pharma Services
Neptune, New Jersey, United States, 07753
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00935506     History of Changes
Other Study ID Numbers: CV197-004
First Posted: July 9, 2009    Key Record Dates
Last Update Posted: February 23, 2011
Last Verified: April 2010

Additional relevant MeSH terms:
Cardiovascular Diseases
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Aspirin
Clopidogrel
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents